Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

bioAffinity Technologies, Inc. Director's Dealing 2025

Jan 14, 2025

35439_dirs_2025-01-14_8a37fd26-99b8-4b17-a28b-13b85ae9d5de.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2025-01-10

Reporting Person: Reveles Xavier Trinidad (Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-10 Common Stock A 21604 Acquired 41943 Direct

Footnotes

F1: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025.